Bicara Therapeutics Inc. Common Stock

NASDAQ BCAX
$12.06 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
709.57M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
248.09M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
54.46M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-30.77 %

Upcoming events Bicara Therapeutics Inc. Common Stock

All events
No upcoming events scheduled

Stock chart Bicara Therapeutics Inc. Common Stock

Stock analysis Bicara Therapeutics Inc. Common Stock

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-7.88 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
5.95 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-3.40 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
6.32 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-19.62 -50.00

Price change Bicara Therapeutics Inc. Common Stock per year

8.71$ 27.07$
Min Max

Summary analysis Bicara Therapeutics Inc. Common Stock

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Bicara Therapeutics Inc. Common Stock

Revenue and net income Bicara Therapeutics Inc. Common Stock

All parameters

About company Bicara Therapeutics Inc. Common Stock

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Address:
116 Huntington Avenue, Boston, MA, United States, 02116
Company name: Bicara Therapeutics Inc. Common Stock
Issuer ticker: BCAX
ISIN: US0554771032
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2024-09-13
Sector: Healthcare
Industry: Biotechnology
Site: https://www.bicara.com